Noxilizer is a provider of ultra-low temperature nitrogen dioxide (NO₂) terminal sterilization used by pharmaceutical, biotechnology, and medical device manufacturers, including for drug-device combination products. Its NO₂ platform is positioned as a validated alternative to ethylene oxide (EtO), with FDA approvals/clearance and EMA authorization cited in the articles. The company offers proprietary sterilization equipment and consumables plus R&D, packaging and design consulting, validation, and technical support. Noxilizer emphasizes safety and sustainability—its process is described as non-carcinogenic with emissions that meet room air quality standards—and compatibility with sensitive biologics and delivery systems. The platform supports fast cycle times and in-house use to improve supply chain reliability. The company plans to broaden availability of NO₂ sterilization globally to meet rising demand as EtO capacity tightens. Noxilizer, Inc. is a Baltimore, MD-based sterilization technology company serving the medical, pharmaceutical and hospital markets. Founded in 2004 and led by President & CEO Lawrence Bruder, the company develops technologies that use nitrogen dioxide as a sterilization solution for pharmaceutical, biotech and medical device companies as well as hospitals. Noxilizer has offices in the US and Japan. The company received an equity investment from Industrial Growth Platform, Inc. to support its growth. The investment was described as intended to help Noxilizer become a global player in the sterilization industry. The amount of the transaction was not disclosed.

Total raised

$30M

Funding rounds

2

Latest round

Equity

Latest activity

Sep 2025